MedTrace Logo

Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

NCT00619268 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2013-02-15

No results posted yet for this study

Summary

The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.

Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®, or Sutent® or IFN+Avastin®.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Temsirolimus

25 mg once per week administered intravenously

DRUG

Bevacizumab

10 mg/kg \* 1 time /2 weeks administered intravenously

DRUG

Sunitinib

50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off

DRUG

Interferon alpha-2a

Administered subcutaneously as 9 MU three times per week

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Sylvie NEGRIER, MD, PhD · Centre Leon Berard

  • Bernard ESCUDIER, MD · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619268 on ClinicalTrials.gov